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The  mechanism  whereby  passively-transferred antibodies lead to  enhance- 
ment of tumor allografts in mice is still unclear. Different hypotheses have been 
derived from conflicting results on similarly constructed experiments, and con- 
troversy  extends  to  the  immunoglobulin  class  of  the  responsible  antibodies 
(1-8).  However,  the  absolute  quantity of antibody used  has not  been  deter- 
mined,  which prevents resolution of these discrepancies. We have  determined 
immunochemically  the  amounts  of  specific  alloantibody  in  three  purified 
mouse  immunoglobulin  preparations  and  have  shown  that  IgM,  IgG1,  and 
IgG2 antibodies are all capable of inducing tumor enhancement  when  used in 
adequate concentrations. 
Materials and Methods 
Mice.--All  animals used  were  purchased from  the Jackson Laboratories, Bar  Harbor, 
Maine. 
Tumor.--Sarcoma  I  (SaI), a strain A fibrosarcoma, was kindly provided by Dr. N. Kaliss, 
Jackson Laboratories. It was maintained in the ascites form by serial passage in A/J mice. 
Allografts consisted of 106 SaI ascites cells, harvested 8 days after inoculation,  suspended  in 
0.1 ml of sterile Hank's balanced salt solution and injected subcutaneously (s.c.) in the backs 
of the recipient mice. 
Preparation of Immune A sdtes.--30 female C57BL/6 (B6) mice were hyperimmunized with 
A/J spleen cells. Ascites was then induced by four intraperitoneal (i.p.) injections of complete 
Freund's adjuvant (Difco Laboratories, Inc., Detroit, Mich.). 
Fractionation of Ascitic  Fluid.--The  hemagglutinating activity of  the material was  fol- 
lowed with the polyvinylpyrrolidone  (PVP) method (9). 
IgM:  IgM was obtained from the ascending  limb of the excluded fraction of Sephadex 
G-200 gel filtration (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). A contaminating 
a-globulin was removed by Pevikon block electrophoresis  (10). 
IgG:  IgG was separated by anion exchange chromatography through DEAE-Sephadex, 
(pH 7, 0.001 M, Tris) (Pharmacia Fine Chemicals). By elution with starting buffer IgG2 only 
was found in the first fractions while most of the IgG1 appeared in the last fractions, con- 
taminated with IgG2. The beginning and final fractions were separately pooled and each was 
freed of transferrin by Sephadex  G-100 gel filtration (Pharmacia Fine Chemicals).  Protein 
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content was determined by absorbance at 280 nm 1  and by the method of Lowry (12), with bo- 
vine serum albumin (BSA) (Schwartz-Mann Div., Becton, Dickinson & Co., Orangeburg, N. 
Y.), as standard.  Immunoglobulin concentration  was found by radial immunodiffusion (13). 
Purity  of  the  fractions  was  ascertained  by  immunoelectrophoresis  and  immunoglobulin 
classes were identified by double-diffusion in agar (14). 
Determination of Specific Antibody Content.--The single-dilution radioimmunoassay method 
of Paul and Esposito (15) was used with minor modifications. Briefly, an aliquot of each anti- 
body preparation  was trace-labeled  (15) with  12~I (New England  Nuclear,  Boston, Mass.) 
achieving approximately one atom of I and 0.002 of 125I  per molecule of immunoglobulin. Anti- 
body uptake was determined with l0 T nucleated spleen cells pretreated  with 0.25% glutaral- 
dehyde,  (Sigma Chemical Co., St. Louis, Mo.)  1-ml vol of different dilutions of labeled im- 
munoglobulins were incubated with glutaraldehyde-treated  A/J or B6 spleen cells for 2 h at 
22°C with continuous mixing. After incubation, the cellular contents were washed eight times 
in chilled BSS, and bound radioactivity  was determined in a gamma-counter  (Superscaler II, 
Nuclear Chicago Corp., Des Plains, Ill.), using a 20--80  kev energy range. 
RESULTS 
Antibody  Concentration  in  Immunoglobulin  Fractions.--Three  immuno- 
globulin  fractions,  isolated  from  two  separate  pools of immune  ascites,  were 
studied  as  shown  in  Table  I.  The  recovery of immunoglobulins  (not  shown) 
varied from  15 %  to 30%  from the concentrations in the starting fluid. 
Specific Antibody  Content of the Three Immunoglobulin  Preparations.--Table 
II depicts the procedure for the estimation of the total antibody concentration 
in  the  labeled  fractions. 
Enhancement of SaI.--In  experiment  1, groups of three  male B6 mice each 
were injected s.c. with tumor and simultaneously i.p.  with different quantities 
of immunoglobulin  preparations,  as shown in Table III. The highest  doses  of 
IgM used, 30  15  ~g, suppressed  tumor growth,  while lower doses of the same 
preparation  enhanced  it.  Treatment  of  the  IgM  preparation  with  0.1  M 
2-mercaptoethanol  (not shown) resulted in loss of both enhancing and suppres- 
sive  effects;  IgG1  and  IgG2  were  not  affected  by this  treatment.  Thus,  the 
activities found in the IgM preparation were not due to undetected contamina- 
tion  with  antibodies  of either  IgG class.  Enhancement  resulted  from  the  in- 
jection of 0.06  ~g of IgG1 in three of three  recipients;  the same dose of IgG2 
induced enhancement in only one of three mice. Thus,  the IgG2 contaminant 
in IgG1 is unlikely to be responsible for its enhancing properties. 
In experiment  2,  larger  quantities  of purified  immunoglobulins  were  avail- 
able. As shown in Table III, again high (25-50 ug) doses of IgM were suppres- 
sive  of  tumor  growth  while  lower  ones  led  to  enhancement.  IgG2  in  molar 
concentrations ~100-fold higher (600 ~g) also suppressed tumor growth. Doses 
of 200 ~g of either IgG2 or IgG1 resulted in enhancement. Unfortunately, IgGl 
was not available  in quantities  that permitted  the use of the  600 ~g dose.  At 
the  lower  end  of the  scale,  again  IgG1  and  IgM  were  slightly  more  efficient 
than  IgG2 in  inducing  enhancement  (in molar  terms). 
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TABLE I 
Protein and Immunoglobulin  Content of A scitic Fluid Fractions 
Protein content  Immunoglobulin  content (Mancini assay) 
Preparation 
Absorbance (280 nm)  Lowry  Specific  Ig  Other Ig  Total 
mg/ml  rag/rat  rag/ral  rag/ral  rag/ral 
Exp. 1 
IgM  1.5  1.9  1.1  0  1.1 
IgG2  2.7  3.0  2.0  0  2.0 
IgGl  3.2  3.5  1.9  0.4*  2.3 
Exp. 2 
IgM  1.9  2.7  1.45  0  1.48 
IgG2  2.8  3.0  2.25  0  2.25 
IgGl  2.9  3.4  1.6  0.3*  1.90 
* IgG2. 
TABLE II 
Specific A ntibody Content of Immunoglobulin  Preparations 
Prepara-  Spec act  Ig  A Counts  from aliquots  containing:  Specific antlbody~t (/~g/ml 
tlon  content*  I0  ~g  50/~g  100/~g  unlabeled preparations) 
cpm/Izg  mg/ml 
Exp. 1 
IgM  1.91  X  103  1.0  439  2,465  5,122  27.5 
IgG2  15.00 X  103  1.9  2,908  13,951  31,833  40 
IgG1  13.4  X  103  2.1  2,151  10,822  22,193  37  (IgG1 30, IgG2 7) 
Exp. 2 
IgM  2.27  X  103  1.3  357  2,039  4,209  22 
IgG2  9.48  X  103  2.1  2,213  10,870  20,981  45.5 
IgG1  8.54  X  103  1.8  1,811  8,875  16,021  36.5 (IgGl 31, IgG2 5.8) 
* Estimated by radial immunodiffusion. 
Calculations: (a) Spec act =  cpm/immunoglobulin  concentration  (jug);  (b)Acount =  (cpm on A/J) -- (cpm 
on B6); (c) Specifically  bound antibody (SBA) =  (Acount/spcc act) (/~g);  (d) Concentration of bindable anti- 
body =  (SBA at given dilution) X  (dilution) X  (protein concentration  in unlabeled preparation/protein  con- 
centration in labeled preparation). 
Table IV shows the effect of IgM given together with either IgG1 or IgG2. 
Suppressive doses of IgM were neutralized by IgG1  and led to enhancement 
while IgM plus IgG2 was still suppressive. In subenhancing  doses both IgG2 
and IgG1 had additive effects to IgM so that the mixtures led to enhancement. 
DISCUSSION 
Quantitative methodology developed for the estimation of Rh antibody in 
immunoglobulin preparation (15) has allowed comparison of the effect on tumor 
growth of antibodies  of different immunoglobulin classes in similar molar con- 
centrations.  IgM suppressed the initial growth of the tumor when used in high 
concentrations,  presumably because it is cytolytic for the neoplastic  cells (7) 
and so did IgG2 in much higher doses, as could perhaps  be expected from its 
relatively lower complement-fixing efficiency. In lower dosage, both led to en- 
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TABLE  III 
Modification of the Growth of Sal in B6 Hosts by Specific Antibodies 
Tumor 
Preparation  Quantity injected  Moleculesx  101s~;  at day  Death withat  growingdays  tumor 
8 
/,tg 
Total immunoglobulins 
Nonimmune  300  0/3  --* 
Ascitic fluid  30  0/3  --* 
30 rag. prot./ml  3  0/3  --* 
Immune  300  3/3  14--19--20 
Ascitic fluid  30  3/3  18--18--19 
28 mg prot./ml  3  3/3  17--17--24 
Exp.  1  Specific antibody 
IgG2  3  11.3  3/3  13--15--19 
0.3  1.13  3/3  14--16--23 
0.06  0.22  1/3  22  (two without  tumors) 
0.03  0.11  0/3  --* 
IgG1  (+IgG2)  3  11.3  3/3  11--15--15 
0.3  1.13  3/3  14--17--19 
0.06  0.22  3/3  13--20--22 
0.03  0.11  1/3  19  (two without  tumors) 
IgM  30  20.1  0/3  --* 
15  10  1/3  12  (two without  tumors) 
1.5  1  3/3  15--18--21 
0.15  0.1  2/3  16--20  (one without  tumor) 
Exp. 2 
IgG2 
IgG1 
IgM 
600  2,300  0/2  --* 
200  750  2/2  14--17 
60  230  3/3  15--17--17 
20  80  3/3  15--19--19 
6  23  3/3  17--19--23 
0.6  2.3  3/3  19--21--33 
0.06  0.23  3/3  21--21--26 
0.03  0.12  0/3  --  (1 died at day 39 w/o tumor) 
0.15  0.06  0/3  --* 
200  750  2/2  17--21 
20  75  2/2  17--17 
2  7.5  3/3  19--19--21 
0.2  0.8  3/3  17--21--23-- 
0.1  0.4  3/3  17 --21 --21 
0.05  0.2  2/3  19--21  (one without  tumor) 
0.02  0.1  1/3  21--  (two without  tumor) 
0.01  0.05  0/3  --* 
50  38  0/2  --* 
25  19  0/2  --* 
12.5  10  3/3  19--21--23 
6  5  3/3  19--21--21 
3  2.5  3/3  17--19--21 
1.5  1.26  3/3  8--19--21 
0.8  0.6  3/3  21--21--23 
0.4  0.3  3/3  17--17--21 
0.2  0.15  3/3  19--19--21 
0.1  0.07  2/3  17--21  (one without  tumor) 
0.05  0.03  0/3  --* 
* No deaths within 30 days. 
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TABLE  IV 
Growth of SaI AUografts in Hosts Given Passive IgM Plus Either IgG1  or IgG2 
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Tumor growth  Death with growing  tumor 
25 p,g IgM -t- 60 Izg IgG2  0/2  0/2 
0.05 #g IgM "k 0.03/~g IgG2  5/,5  3/5 
25/~g IgM -b 10 #g IgGl  2/2  2/2 
50/~g IgM -b 10 #g IgG1  2/2  2/2 
0.05 IZg IgM -[- 0.02 #g IgG1  5/5  4/5 
however, quantities of about 2 X  105 antibody molecules per injected tumor cell 
caused enhancement with the three immunoglobulins; 1 X  105 did so for IgG1 
and IgM but not for IgG2. The wide range of survival times and the small 
number of animals per group preclude further elaboration of the data. Mixtures 
of suppressive doses of IgM and enhancing amounts of IgG2 were suppressive 
of tumor growth, while similar mixtures of IgM and IgG1 led to enhancement. 
This experiment suggests differences in the mechanisms of action of IgG2 and 
IgG1 as proposed by Voisin (2), although differences in avidity may (also) be at 
work. In low concentrations, both IgG2 and IgG1  exerted effects additive to 
those of IgM. 
It is probable that avidity, in addition to quantity, is important in determin- 
ing the enhancing efficiency of antibody, and we are currently trying to relate 
K-values for antibodies of the different immunoglobulin classes  to enhancing 
efficiency. Studies are  also  under way to  determine whether  the mechanism 
whereby the different immunoglobulins lead to tumor enhancement is the same. 
In conclusion, these results indicate that enhancement is  a  property of anti- 
bodies of most or all immunoglobulin classes and that the contradictory results 
of other studies may result from quantitative differences. 
SUMMARY 
The concentration of specific alloantibody in purified mouse immunoglobulin 
preparations  was determined. When passively transferred in adequate doses, 
IgM, IgG1, and IgG2 antibodies all induced tumor enhancement in allogeneic 
hosts. IgM and IgG2 antibodies in high concentration led to inhibition of tumor 
growth. IgM and either IgG1 or IgG2 had additive effects on tumor enhance- 
ment. IgG1, but not IgG2, suppressed the inhibitory effect of IgM in high con- 
centration. 
We thank Doctors N. Kaliss, S.  Kochwa, and R.  E.  Rosenfield for their generous advice 
and criticism. 
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